COL1A1 and glioblastoma: Analysis of patient survival related to COL1A1 expression showed that mesenchymal GBM subtype displayed a significantly shorter survival (MS: 10.4 months) for COL1A1 high tumors, compared to COL1A1 low (MS: 17.9 months) tumors.